Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease

Karamat Hussain Shah Bukhari, Asma Asghar, Najma Perveen, Arshad Hayat, Sermad Ahmad Mangat, Kamil Rehman Butt, Mohammad Abdullah, Tehreem Fatima, Ahmad Mustafa, Talal Iqbal
doi: https://doi.org/10.1101/2021.02.02.21250840
Karamat Hussain Shah Bukhari
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Asma Asghar
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Najma Perveen
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arshad Hayat
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sermad Ahmad Mangat
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamil Rehman Butt
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Abdullah
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mohammadabdullah_786@hotmail.com
Tehreem Fatima
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmad Mustafa
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Talal Iqbal
1Department of Medicine, Combined Military Hospital Lahore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To evaluate the efficacy of ivermectin (IVM) as an addition to the standard of care (SOC) treatment in COVID-19 patients with mild and moderate disease

Materials and Methods A randomized clinical trial (Trial registration # NCT04392713) was carried out at Combined Military Hospital Lahore from March 15, 2020, to June 15, 2020. Eighty-six patients with reverse transcriptase-polymerase chain reaction (RT-PCR) proven SARS-CoV-2 infection completed the trial protocol. Patients were stratified via the lottery method into two groups. Group A was administered standard of care (SOC) treatment as per existing hospital guidelines whereas group B was given ivermectin (single dose of 12 milligrams) along with SOC treatment. PCR was repeated at 72 hours, 7th day, and at 14th day of admission for both the groups and the point at which the PCR became negative was noted. Complete blood counts, liver function tests and renal function tests were done at recruitment, 7th day, and 14th day. The primary outcome was the viral clearance, measured as days to achieve PCR negativity. The secondary outcome was the development of any adverse side effects pertinent to ivermectin or derangement in baseline laboratory parameters.

Results In group A, 36 (80%) participants were males, and 9 (20%) were females, whereas in group B, 37 (90.2%) were males and 4 (9.8%) were females. Mean age was 39.0± 12.6 and 42.2 ± 12.0 years for groups A and B, respectively (p= 0.394). There was early viral clearance in group B as compared to group A (p=0.001). No adverse reaction or derangements in laboratory parameters was noted in the intervention arm during the trial period.

Conclusion In the intervention arm, early viral clearance was observed and no side effects were documented. Therefore ivermectin is a potential addition to the standard care of treatment in COVID-19 patients.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04392713

Funding Statement

Not applicable

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

CMH Lahore Ethics Review Board 169/2020

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data can be made available from authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted February 05, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
Karamat Hussain Shah Bukhari, Asma Asghar, Najma Perveen, Arshad Hayat, Sermad Ahmad Mangat, Kamil Rehman Butt, Mohammad Abdullah, Tehreem Fatima, Ahmad Mustafa, Talal Iqbal
medRxiv 2021.02.02.21250840; doi: https://doi.org/10.1101/2021.02.02.21250840
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
Karamat Hussain Shah Bukhari, Asma Asghar, Najma Perveen, Arshad Hayat, Sermad Ahmad Mangat, Kamil Rehman Butt, Mohammad Abdullah, Tehreem Fatima, Ahmad Mustafa, Talal Iqbal
medRxiv 2021.02.02.21250840; doi: https://doi.org/10.1101/2021.02.02.21250840

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)